Calyxt Files Registration Statement for Proposed Initial Public Offering
June 23 2017 - 12:45PM
Business Wire
Regulatory News:
Cellectis S.A. (Alternext : ALCLS ; Nasdaq : CLLS) and Calyxt,
Inc. announced that Calyxt has publicly filed a registration
statement on Form S-1 with the U.S. Securities and Exchange
Commission (SEC) relating to a proposed initial public offering
(IPO) of shares of Calyxt common stock. Calyxt is Cellectis’ 100%
owned gene editing agriculture company. The number of shares to be
offered and the price range for the offering have not yet been
determined, although Cellectis intends to retain majority ownership
of Calyxt.
Citigroup, Credit Suisse and Jefferies are acting as joint
book-running managers for the proposed offering. Wells Fargo
Securities is acting as lead manager and Ladenburg Thalmann is
acting as co-manager.
This offering will be made only by means of a prospectus
(included in the registration statement on Form S-1). When
available, a copy of the preliminary prospectus may be obtained
from Citigroup Global Markets Inc., c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (800) 831-9146; Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, One Madison Avenue, New York, NY
10010, or by telephone at (800) 221-1037, or by email at
newyork.prospectus@credit-suisse.com; or Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by
e-mail at Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. The
registration statement is available at
https://www.cellectis.com/FINAL.calyxt.s1.june.23.2017.pdf. These
securities may not be sold, nor may offers to buy be accepted,
prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
This press release contains inside information within the
meaning of Article 7(1) of the EU Market Abuse Regulation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170623005487/en/
MediaJennifer Moore, VP CommunicationsPhone:
917-580-1088email: media@calyxt.com / media@cellectis.comorCaitlin
Kasunich / Nick OpichKCSA Strategic CommunicationsPhone:
212-896-1241 / 212-896-1206email: ckasunich@kcsa.com / nopich@kcsa.comorInvestor RelationsSimon
Harnest, VP Corporate Strategy and FinancePhone: 646-385-9008email:
simon.harnest@cellectis.com
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Mar 2023 to Mar 2024